person · Reporting owner

DIMICK NEIL F

Disclosed activity across 5 companies

Tapewire entity: 74899
SEC CIK: 0001248380

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
RESOURCES CONNECTION, INC.RGP · Entity 6553	Director	September 26, 2025	September 29, 2025
Viatris IncVTRS · Entity 3277	Director	March 21, 2022	March 23, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

RESOURCES CONNECTION, INC.

Report date September 26, 2025 · Filed September 29, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	68,682	Reported balance After 2025-09-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-09-26 · Grant · Acquired 929 · Balance 68,682 F1: Represents dividend equivalent phantom shares accrued on previously awarded phantom shares in accordance with the terms of the Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. These shares of phantom stock will become payable in cash to the reporting person upon separation from service as a director in accordance with the reporting person's election under the Directors Deferred Compensation Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents dividend equivalent phantom shares accrued on previously awarded phantom shares in accordance with the terms of the Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. These shares of phantom stock will become payable in cash to the reporting person upon separation from service as a director in accordance with the reporting person's election under the Directors Deferred Compensation Plan.

Viatris Inc

Report date March 21, 2022 · Filed March 23, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	75,200	Reported balance After 2022-03-21 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-03-21 · Exercise / conversion · Acquired 166 · Balance 75,200 F1: Fractional shares have been rounded up in connection with the settlement described in footnote 2 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. F2: The total reported in Column 5 has been adjusted by 30 shares to correct an understatement of total holdings first reflected in the reporting person's Form 4 filed on March 4, 2022.
Dividend Equivalent UnitsSEC Table II · derivative / convertible security	Direct	165.5224	Reported balance After 2022-03-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-03-21 · Grant · Acquired 165.5224 · Balance 165.5224 F3: Represents dividend equivalent units (DEUs) that accrued with respect to RSUs previously granted on March 2, 2021. The DEUs vested upon accrual as the underlying RSUs had previously vested.
Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2022-03-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-03-21 · Exercise / conversion · Disposed 165.5224 · Balance 0 F3: Represents dividend equivalent units (DEUs) that accrued with respect to RSUs previously granted on March 2, 2021. The DEUs vested upon accrual as the underlying RSUs had previously vested.

Filing footnotes · ownership attribution and instrument terms

F1: Fractional shares have been rounded up in connection with the settlement described in footnote 2 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan.

F2: The total reported in Column 5 has been adjusted by 30 shares to correct an understatement of total holdings first reflected in the reporting person's Form 4 filed on March 4, 2022.

F3: Represents dividend equivalent units (DEUs) that accrued with respect to RSUs previously granted on March 2, 2021. The DEUs vested upon accrual as the underlying RSUs had previously vested.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Alliance HealthCare Services, Inc

Report date August 21, 2017 · Filed August 22, 2017

Section 16 reporting ended · disclosed 2017-08-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-08-21 transaction · row 1 1 source row Row 1 · 2017-08-21 · Disposition to issuer · Disposed 70,817 · Balance 0 F1: Disposed of pursuant to the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of April 10, 2017 by and among the Issuer, Tahoe Investment Group Co., Ltd., THAIHOT Investment Company Limited, THAIHOT Investment Company US Limited and Alliance Healthcare Services Merger Sub Limited. Each share of Issuer common stock held by the reporting person was cancelled in the merger and converted into the right to receive $13.25 in cash per share, without interest and less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of April 10, 2017 by and among the Issuer, Tahoe Investment Group Co., Ltd., THAIHOT Investment Company Limited, THAIHOT Investment Company US Limited and Alliance Healthcare Services Merger Sub Limited. Each share of Issuer common stock held by the reporting person was cancelled in the merger and converted into the right to receive $13.25 in cash per share, without interest and less any applicable withholding taxes.

Mylan II B.V.

Report date November 16, 2020 · Filed November 18, 2020

Section 16 reporting ended · disclosed 2020-11-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2020-11-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-11-16 · Disposition to issuer · Disposed 51,263 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.
Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $45.72 · Expires 2024-04-11	Direct	Reported balance After 2020-11-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-16 · Disposition to issuer · Disposed 2,974 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F4: These options vested on April 11, 2015.
Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $50.66 · Expires 2025-11-17	Direct	Reported balance After 2020-11-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-16 · Disposition to issuer · Disposed 2,603 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F5: These options vested on May 1, 2016.
Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $46.27 · Expires 2026-02-17	Direct	Reported balance After 2020-11-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-16 · Disposition to issuer · Disposed 2,788 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F6: These options vested on February 17, 2017.
Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $45.18 · Expires 2027-03-03	Direct	Reported balance After 2020-11-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-16 · Disposition to issuer · Disposed 2,928 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F7: These options vested on March 3, 2018.
Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $40.97 · Expires 2028-03-02	Direct	Reported balance After 2020-11-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-16 · Disposition to issuer · Disposed 2,984 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F8: These options vested on March 2, 2019.
Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $27.45 · Expires 2029-03-01	Direct	Reported balance After 2020-11-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-16 · Disposition to issuer · Disposed 4,352 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F9: These options vested on March 2, 2020.
Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2030-03-02	Direct	Reported balance After 2020-11-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-11-16 · Disposition to issuer · Disposed 6,151 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F10: These options will vest on March 2, 2021.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2020-11-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-11-16 · Disposition to issuer · Disposed 9,440 · Balance 0 F11: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F12: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination.

F4: These options vested on April 11, 2015.

F5: These options vested on May 1, 2016.

F6: These options vested on February 17, 2017.

F7: These options vested on March 3, 2018.

F8: These options vested on March 2, 2019.

F9: These options vested on March 2, 2020.

F10: These options will vest on March 2, 2021.

F11: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination.

F12: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021.

WebMD Health Corp.

Report date September 15, 2017 · Filed September 15, 2017

Section 16 reporting ended · disclosed 2017-09-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-09-15 transaction · row 1 1 source row Row 1 · 2017-09-15 · Other · Disposed 13,862 · Balance 0 F1: Sold in a tender offer made by Diagnosis Merger Sub, Inc., a Delaware Corporation ("Purchaser") and a wholly-owned subsidiary of MH Sub I, LLC, a Delaware limited liability company ("Parent"), to purchase all of the issued and outstanding shares of common stock of WebMD Health Corp., a Delaware corporation ("WebMD"), for $66.50 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of July 24, 2017, by and among WebMD, Purchaser, and Parent (the "Merger Agreement").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.07 · Expires 2018-01-01	Direct	Reported balance After 2017-09-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.54 · Expires 2019-01-01	Direct	Reported balance After 2017-09-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-09-15 · Disposition to issuer · Disposed 8,888 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.49 · Expires 2020-01-01	Direct	Reported balance After 2017-09-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.55 · Expires 2022-01-01	Direct	Reported balance After 2017-09-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.34 · Expires 2023-01-01	Direct	Reported balance After 2017-09-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.50 · Expires 2024-01-01	Direct	Reported balance After 2017-09-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.55 · Expires 2025-01-01	Direct	Reported balance After 2017-09-15 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.30 · Expires 2026-01-01	Direct	Reported balance After 2017-09-15 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.57 · Expires 2027-01-01	Direct	Reported balance After 2017-09-15 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.

Filing footnotes · ownership attribution and instrument terms

F1: Sold in a tender offer made by Diagnosis Merger Sub, Inc., a Delaware Corporation ("Purchaser") and a wholly-owned subsidiary of MH Sub I, LLC, a Delaware limited liability company ("Parent"), to purchase all of the issued and outstanding shares of common stock of WebMD Health Corp., a Delaware corporation ("WebMD"), for $66.50 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of July 24, 2017, by and among WebMD, Purchaser, and Parent (the "Merger Agreement").

F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 02, 2020 Filed Mar 4, 2020 18:32 UTC	Mylan II B.V. MYL · Entity 16217	GrantNon-Employee Director Stock Option-Right to Buy · Derivative	6,151	$0.00 Strike: $17.48	$0.00	Disclosure SEC source: 0000899243-20-007020 · doc4.xml · derivative · entry 3 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,151 Underlying: Ordinary Shares · 6,151 shares Expires 2030-03-02 F2 · derivative.exercise_date: These options will vest in full on March 2, 2021 and expire on March 2, 2030. Read SEC document
March 02, 2020 Filed Mar 4, 2020 18:32 UTC	Mylan II B.V. MYL · Entity 16217	Tax withholdingOrdinary Shares	1,754	$17.48	$30,659.92	Disclosure SEC source: 0000899243-20-007020 · doc4.xml · nonDerivative · entry 2 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,263 F1 · shares: Represents withholding of ordinary shares for the U.K. tax liability associated with the settlement of the restricted stock units (RSUs) granted on March 1, 2019. Read SEC document
March 02, 2020 Filed Mar 4, 2020 18:32 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionOrdinary Shares	6,011	$0.00	$0.00	Disclosure SEC source: 0000899243-20-007020 · doc4.xml · nonDerivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 02, 2020 Filed Jan 3, 2020 23:38 UTC	RESOURCES CONNECTION, INC. RECN · Entity 6553	GrantPhantom Stock · Derivative	6,124	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001746673-20-000018 · edgardoc.xml · derivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,692 Underlying: Common Stock · 6,124 shares Expires not disclosed F1 · derivative.exercise_date: Represents credit of deferred compensation to reporting person's deferred stock account under the Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in cash to the reporting person upon separation from service as a director. F1 · derivative.expiration_date: Represents credit of deferred compensation to reporting person's deferred stock account under the Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in cash to the reporting person upon separation from service as a director. Read SEC document
March 02, 2019 Filed Mar 5, 2019 18:21 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionRestricted Stock Units · Derivative	4,028	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-006220 · doc4.xml · derivative · entry 5 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,028 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 2, 2019. F4 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 2, 2019. Read SEC document
March 02, 2019 Filed Mar 5, 2019 18:21 UTC	Mylan II B.V. MYL · Entity 16217	Tax withholdingOrdinary Shares	1,639	$27.45	$44,990.55	Disclosure SEC source: 0000899243-19-006220 · doc4.xml · nonDerivative · entry 2 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,006 F1 · shares: Represents withholding of ordinary shares for the U.K. tax liability associated with the settlement of the restricted stock units (RSUs) granted on March 2, 2018. Read SEC document
March 02, 2019 Filed Mar 5, 2019 18:21 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionOrdinary Shares	4,028	$0.00	$0.00	Disclosure SEC source: 0000899243-19-006220 · doc4.xml · nonDerivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2019 Filed Mar 5, 2019 18:21 UTC	Mylan II B.V. MYL · Entity 16217	GrantRestricted Stock Units · Derivative	6,011	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-006220 · doc4.xml · derivative · entry 4 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,011 Underlying: Ordinary Shares · 6,011 shares Expires not disclosed F3 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2020. F3 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2020. Read SEC document
March 01, 2019 Filed Mar 5, 2019 18:21 UTC	Mylan II B.V. MYL · Entity 16217	GrantNon-Employee Director Stock Option-Right to Buy · Derivative	4,352	$0.00 Strike: $27.45	$0.00	Disclosure SEC source: 0000899243-19-006220 · doc4.xml · derivative · entry 3 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,352 Underlying: Ordinary Shares · 4,352 shares Expires 2029-03-01 F2 · derivative.exercise_date: These options will vest in full on March 2, 2020 and expire on March 1, 2029. Read SEC document
January 02, 2019 Filed Jan 4, 2019 23:59 UTC	RESOURCES CONNECTION, INC. RECN · Entity 6553	GrantPhantom Stock · Derivative	7,179	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001332688-19-000006 · edgardoc.xml · derivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,179 Underlying: Common Stock · 7,179 shares Expires not disclosed F1 · derivative.exercise_date: Represents credit of deferred compensation to reporting person's deferred stock account under the Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in cash to the reporting person upon separation from service as a director. F1 · derivative.expiration_date: Represents credit of deferred compensation to reporting person's deferred stock account under the Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in cash to the reporting person upon separation from service as a director. Read SEC document
March 03, 2018 Filed Mar 6, 2018 20:18 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionRestricted Stock Units · Derivative	3,653	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-18-006540 · doc4.xml · derivative · entry 5 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 3, 2018. F4 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 3, 2018. Read SEC document
March 03, 2018 Filed Mar 6, 2018 20:18 UTC	Mylan II B.V. MYL · Entity 16217	Tax withholdingOrdinary Shares	1,525	$40.97	$62,479.25	Disclosure SEC source: 0000899243-18-006540 · doc4.xml · nonDerivative · entry 2 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,617 F1 · shares: Represents withholding of ordinary shares for the U.K. tax liability associated with the settlement of the restricted stock units (RSUs) granted on March 3, 2017. Read SEC document
March 03, 2018 Filed Mar 6, 2018 20:18 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionOrdinary Shares	3,653	$0.00	$0.00	Disclosure SEC source: 0000899243-18-006540 · doc4.xml · nonDerivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 02, 2018 Filed Mar 6, 2018 20:18 UTC	Mylan II B.V. MYL · Entity 16217	GrantRestricted Stock Units · Derivative	4,028	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-18-006540 · doc4.xml · derivative · entry 4 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,028 Underlying: Ordinary Shares · 4,028 shares Expires not disclosed F3 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2019. F3 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2019. Read SEC document
March 02, 2018 Filed Mar 6, 2018 20:18 UTC	Mylan II B.V. MYL · Entity 16217	GrantNon-Employee Director Stock Option-Right to Buy · Derivative	2,984	$0.00 Strike: $40.97	$0.00	Disclosure SEC source: 0000899243-18-006540 · doc4.xml · derivative · entry 3 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,984 Underlying: Ordinary Shares · 2,984 shares Expires 2028-03-02 F2 · derivative.exercise_date: These options will vest in full on March 2, 2019 and expire on March 2, 2028. Read SEC document
January 02, 2018 Filed Jan 4, 2018 17:34 UTC	RESOURCES CONNECTION, INC. RECN · Entity 6553	GrantPhantom Stock · Derivative	6,389	$15.65	$99,987.85	Disclosure SEC source: 0001248380-18-000003 · edgardoc.xml · derivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,389 Underlying: Common Stock · 6,389 shares Expires not disclosed F1 · derivative.exercise_price: Represents the credit of deferred compensation to the Reporting Person?s deferred stock account under the Issuer?s Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in cash to the Reporting Person upon the Reporting Person?s separation from service as a director. F1 · derivative.exercise_date: Represents the credit of deferred compensation to the Reporting Person?s deferred stock account under the Issuer?s Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in cash to the Reporting Person upon the Reporting Person?s separation from service as a director. F1 · derivative.expiration_date: Represents the credit of deferred compensation to the Reporting Person?s deferred stock account under the Issuer?s Directors Deferred Compensation Plan. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in cash to the Reporting Person upon the Reporting Person?s separation from service as a director. Read SEC document
September 15, 2017 Filed Sep 15, 2017 11:40 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $49.57	Not disclosed	Disclosure SEC source: 0000947871-17-000717 · ss59044_4.xml · derivative · entry 10 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2027-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 11:40 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $48.30	Not disclosed	Disclosure SEC source: 0000947871-17-000717 · ss59044_4.xml · derivative · entry 9 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2026-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 11:40 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $39.55	Not disclosed	Disclosure SEC source: 0000947871-17-000717 · ss59044_4.xml · derivative · entry 8 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2025-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 11:40 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $39.50	Not disclosed	Disclosure SEC source: 0000947871-17-000717 · ss59044_4.xml · derivative · entry 7 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2024-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 11:40 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $14.34	Not disclosed	Disclosure SEC source: 0000947871-17-000717 · ss59044_4.xml · derivative · entry 6 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2023-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 11:40 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $37.55	Not disclosed	Disclosure SEC source: 0000947871-17-000717 · ss59044_4.xml · derivative · entry 5 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2022-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 11:40 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $38.49	Not disclosed	Disclosure SEC source: 0000947871-17-000717 · ss59044_4.xml · derivative · entry 4 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2020-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 11:40 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	8,888	Not disclosed Strike: $23.54	Not disclosed	Disclosure SEC source: 0000947871-17-000717 · ss59044_4.xml · derivative · entry 3 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,888 shares Expires 2019-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 11:40 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $41.07	Not disclosed	Disclosure SEC source: 0000947871-17-000717 · ss59044_4.xml · derivative · entry 2 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2018-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 11:40 UTC	WebMD Health Corp. WBMD · Entity 12671	OtherCommon Stock	13,862	$66.50	$921,823.00	Disclosure SEC source: 0000947871-17-000717 · ss59044_4.xml · nonDerivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Sold in a tender offer made by Diagnosis Merger Sub, Inc., a Delaware Corporation ("Purchaser") and a wholly-owned subsidiary of MH Sub I, LLC, a Delaware limited liability company ("Parent"), to purchase all of the issued and outstanding shares of common stock of WebMD Health Corp., a Delaware corporation ("WebMD"), for $66.50 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of July 24, 2017, by and among WebMD, Purchaser, and Parent (the "Merger Agreement"). Read SEC document
August 21, 2017 Filed Aug 22, 2017 16:52 UTC	Alliance HealthCare Services, Inc AIQ · Entity 17292	Disposition to issuerCommon Stock	70,817	$13.25	$938,325.25	Disclosure SEC source: 0000899243-17-020848 · doc4.xml · nonDerivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of April 10, 2017 by and among the Issuer, Tahoe Investment Group Co., Ltd., THAIHOT Investment Company Limited, THAIHOT Investment Company US Limited and Alliance Healthcare Services Merger Sub Limited. Each share of Issuer common stock held by the reporting person was cancelled in the merger and converted into the right to receive $13.25 in cash per share, without interest and less any applicable withholding taxes. Read SEC document
March 03, 2017 Filed Mar 7, 2017 19:26 UTC	Mylan II B.V. MYL · Entity 16217	GrantRestricted Stock Units · Derivative	3,653	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-17-006753 · doc4.xml · derivative · entry 2 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,653 Underlying: Ordinary Shares · 3,653 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 3, 2018. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 3, 2018. Read SEC document
March 03, 2017 Filed Mar 7, 2017 19:26 UTC	Mylan II B.V. MYL · Entity 16217	GrantNon-Employee Director Stock Option - Right to Buy · Derivative	2,928	$0.00 Strike: $45.18	$0.00	Disclosure SEC source: 0000899243-17-006753 · doc4.xml · derivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,928 Underlying: Ordinary Shares · 2,928 shares Expires 2027-03-03 F1 · derivative.exercise_date: These options will vest in full on March 3, 2018 and expire on March 3, 2027. Read SEC document
February 17, 2017 Filed Feb 21, 2017 19:02 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionRestricted Stock Units · Derivative	3,567	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-17-004822 · doc4.xml · derivative · entry 3 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on February 17, 2017. F2 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on February 17, 2017. Read SEC document
February 17, 2017 Filed Feb 21, 2017 19:02 UTC	Mylan II B.V. MYL · Entity 16217	Tax withholdingOrdinary Shares	1,537	$42.05	$64,630.85	Disclosure SEC source: 0000899243-17-004822 · doc4.xml · nonDerivative · entry 2 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,489 F1 · shares: Represents withholding of ordinary shares for the U.K. tax liability associated with the settlement of the restricted stock units (RSUs) granted on February 17, 2016. Read SEC document
February 17, 2017 Filed Feb 21, 2017 19:02 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionOrdinary Shares	3,567	$0.00	$0.00	Disclosure SEC source: 0000899243-17-004822 · doc4.xml · nonDerivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2017 Filed Jan 4, 2017 21:46 UTC	RESOURCES CONNECTION, INC. RECN · Entity 6553	GrantCommon Stock	5,141	$0.00	$0.00	Disclosure SEC source: 0001248380-17-000003 · edgardoc.xml · nonDerivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,273 F1 · date: Non Employee Director Restricted Stock Award Read SEC document
January 01, 2017 Filed Jan 3, 2017 16:13 UTC	WebMD Health Corp. WBMD · Entity 12671	GrantStock Option (right to buy) · Derivative	13,200	$0.00 Strike: $49.57	$0.00	Disclosure SEC source: 0000947871-17-000004 · ss25378_4.xml · derivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2027-01-01 F1 · derivative.exercise_date: 25% of the shares underlying the option are scheduled to vest on each of the first, second, third and fourth anniversary of the date of the grant (fully vested on the 4th anniversary of the grant date). Read SEC document
December 31, 2016 Filed Feb 22, 2017 19:48 UTC	Alliance HealthCare Services, Inc AIQ · Entity 17292	GrantCommon Stock	14,917	$0.00	$0.00	Disclosure SEC source: 0001562180-17-000865 · primarydocument.xml · nonDerivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,817 F1 · shares: Represents a grant of restricted stock units (RSUs) awarded on December 31, 2016 and scheduled to vest on the first anniversary of the grant date, subject to the Participant's continued service with the Company or its Subsidiaries through such date. F2 · balance_after: Balance may include unvested RSUs Read SEC document
December 08, 2016 Filed Dec 9, 2016 17:28 UTC	WebMD Health Corp. WBMD · Entity 12671	SaleCommon Stock	18,740	$52.84	$990,221.60	Disclosure SEC source: 0000947871-16-001757 · ss22912_4.xml · nonDerivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,862 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.77 to $53.04 inclusive. The reporting person undertakes to provide to WebMD Health Corp., any security holder of WebMD Health Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document
November 22, 2016 Filed Nov 23, 2016 18:11 UTC	WebMD Health Corp. WBMD · Entity 12671	Exercise / conversionStock Option (right to buy) · Derivative	13,200	$0.00 Strike: $23.59	$0.00	Disclosure SEC source: 0000947871-16-001713 · ss20681_4.xml · derivative · entry 9 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares underlying the option vested on the first anniversary of the grant date and 1/48 of the shares vested or monthly thereafter over the next three-year period (fully vested on the 4th anniversary of the grant date). The date of grant was ten years prior to the expiration date. Read SEC document
November 22, 2016 Filed Nov 23, 2016 18:11 UTC	WebMD Health Corp. WBMD · Entity 12671	Exercise / conversionStock Option (right to buy) · Derivative	13,200	$0.00 Strike: $40.02	$0.00	Disclosure SEC source: 0000947871-16-001713 · ss20681_4.xml · derivative · entry 8 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2017-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares underlying the option vested on the first anniversary of the grant date and 1/48 of the shares vested or monthly thereafter over the next three-year period (fully vested on the 4th anniversary of the grant date). The date of grant was ten years prior to the expiration date. Read SEC document
November 22, 2016 Filed Nov 23, 2016 18:11 UTC	WebMD Health Corp. WBMD · Entity 12671	Exercise / conversionStock Option (right to buy) · Derivative	8,888	$0.00 Strike: $30.16	$0.00	Disclosure SEC source: 0000947871-16-001713 · ss20681_4.xml · derivative · entry 7 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,888 shares Expires 2018-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares underlying the option vested on each of the first, second, third and fourth anniversary of the date of grant (fully vested on the 4th anniversary of the grant date). The date of grant was ten years prior to the expiration date. Read SEC document
November 22, 2016 Filed Nov 23, 2016 18:11 UTC	WebMD Health Corp. WBMD · Entity 12671	Tax withholdingCommon Stock	5,787	$53.81	$311,398.47	Disclosure SEC source: 0000947871-16-001713 · ss20681_4.xml · nonDerivative · entry 6 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,602 F3 · balance_after: Mr. Dimick received 7,413 shares of WebMD Common Stock upon net share settlement of his exercise of options to purchase 13,200 shares of WebMD Common Stock, with the remaining 5,787 shares being retained by the issuer to pay the exercise price. Read SEC document
November 22, 2016 Filed Nov 23, 2016 18:11 UTC	WebMD Health Corp. WBMD · Entity 12671	Exercise / conversionCommon Stock	13,200	$23.59	$311,388.00	Disclosure SEC source: 0000947871-16-001713 · ss20681_4.xml · nonDerivative · entry 5 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 22, 2016 Filed Nov 23, 2016 18:11 UTC	WebMD Health Corp. WBMD · Entity 12671	Tax withholdingCommon Stock	9,818	$53.81	$528,306.58	Disclosure SEC source: 0000947871-16-001713 · ss20681_4.xml · nonDerivative · entry 4 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,189 F2 · balance_after: Mr. Dimick received 3,382 shares of WebMD Common Stock upon net share settlement of his exercise of options to purchase 13,200 shares of WebMD Common Stock, with the remaining 9,818 shares being retained by the issuer to pay the exercise price. Read SEC document
November 22, 2016 Filed Nov 23, 2016 18:11 UTC	WebMD Health Corp. WBMD · Entity 12671	Exercise / conversionCommon Stock	13,200	$40.02	$528,264.00	Disclosure SEC source: 0000947871-16-001713 · ss20681_4.xml · nonDerivative · entry 3 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 22, 2016 Filed Nov 23, 2016 18:11 UTC	WebMD Health Corp. WBMD · Entity 12671	Tax withholdingCommon Stock	4,982	$53.81	$268,081.42	Disclosure SEC source: 0000947871-16-001713 · ss20681_4.xml · nonDerivative · entry 2 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,807 F1 · balance_after: Mr. Dimick received 3,906 shares of WebMD Common Stock upon net share settlement of his exercise of options to purchase 8,888 shares of WebMD Common Stock, with the remaining 4,982 shares being retained by the issuer to pay the exercise price. Read SEC document
November 22, 2016 Filed Nov 23, 2016 18:11 UTC	WebMD Health Corp. WBMD · Entity 12671	Exercise / conversionCommon Stock	8,888	$30.16	$268,062.08	Disclosure SEC source: 0000947871-16-001713 · ss20681_4.xml · nonDerivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2016 Filed Nov 17, 2016 16:52 UTC	WebMD Health Corp. WBMD · Entity 12671	GrantCommon Stock	1,356	$53.83	$72,993.48	Disclosure SEC source: 0000947871-16-001690 · ss19887_4.xml · nonDerivative · entry 1 DIMICK NEIL F · CIK 0001248380 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,901 F1 · shares: Payment of annual retainer for services as a non-employee member of the Board of Directors and its committees. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.